Inhibitory effect of flavonoid xanthomicrol on triple-negative breast tumor via regulation of cancer-associated microRNAs.

Phytotherapy Research : PTR
Farnoosh AttariMahdi Moridi Farimani

Abstract

Breast cancer is the leading cause of cancer death in women worldwide. Due to the side effects of current chemo-reagents on healthy tissues, it is essential to search for alternative compounds with less toxicity and better efficacy. In the present study, we have investigated the anticancer effects of flavonoid xanthomicrol on the mice breast cancer model using MTT assay, cell cycle and Annexin/PI analysis, colony formation assay, H&E staining, immunohistochemistry, and miRNA analysis. Our results demonstrated that xanthomicrol decreased the cell viability and clonogenic capability, induced G1-arrest and apoptosis in the breast cancer cells in vitro, and caused a significant reduction in the volume and weight of mice tumors in vivo. In addition, xanthomicrol reduced the expression of TNFα, VEGF, MMP9, and Ki67, while upregulating the expression of apoptotic markers such as Bax, caspase3, and caspase9. Finally, the expression of miR21, miR27, and miR125, known as oncomirs, decreased significantly after xanthomicrol administration, while the expression of miR29 and miR34, functioning as tumor suppressors, increased significantly (p < .001). Our data demonstrated that xanthomicrol can induce apoptosis and suppress angiogenesis in b...Continue Reading

References

Mar 22, 2001·British Journal of Clinical Pharmacology·T WalleP V Halushka
Sep 11, 2003·The Lancet Oncology·Peter W Szlosarek, Frances R Balkwill
Jul 21, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·X Wen, T Walle
Jul 27, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xia Wen, Thomas Walle
Jun 19, 2007·Seminars in Cancer Biology·Thomas Walle
Feb 14, 2008·Cell Research·Shuomin ZhuYin-Yuan Mo
Aug 12, 2008·BMC Cancer·Kai TaoG Gary Sahagian
Sep 15, 2012·Progress in Molecular Biology and Translational Science·Edward Croom
Jun 25, 2013·Cancer Research·Mingxia YuZhuoya Li
Jan 8, 2014·Biochemical and Biophysical Research Communications·San-Zhong LiZhou Fei
Aug 21, 2014·Mini Reviews in Medicinal Chemistry·Mohammad FattahiJavier Palazon
Sep 23, 2014·European Journal of Pharmacology·Li FanGuangrong Huang
Sep 26, 2014·BioMed Research International·Neoh Hun Phuah, Noor Hasima Nagoor
Jan 19, 2015·Cancer Chemotherapy and Pharmacology·Edgardo Rivera, Mary Cianfrocca
Apr 18, 2015·Expert Opinion on Pharmacotherapy·Eleni AndreopoulouHayley M McDaid
Sep 27, 2015·Experimental Cell Research·Hang YinMinghai Wei
Dec 19, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Guodong LiFeng Gao
Mar 2, 2016·Current Pharmaceutical Biotechnology·Dongwu LiuZhiwei Chen
Apr 1, 2016·British Journal of Cancer·Carlos Martínez-PérezSimon P Langdon
Oct 8, 2016·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Seyedeh-Somayeh ZamaniSoltan Ahmad Ebrahimi
Jan 13, 2018·Chromosoma·Xiaoming Sun, Paul D Kaufman
Jan 2, 2019·Cancers·Mariam AbotalebDietrich Büsselberg

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis